Medicamen Biotech Segment Revenue Breakdown
₹304.80-2.70%close, 9 Oct 2026
- Market cap
- ₹413 crore
- P/E
- 22.5
- P/B
- 2.85
- ROE
- 14.5%
- Dividend yield
- 1.20%
- 52-week range
- ₹219.46 – ₹411.48
Consolidated revenue breakdown by business segment for Medicamen Biotech.
Medicamen Biotech business segment revenue mix
Breakdown of consolidated revenue by business segment and division.
| Business Segment | Revenue (₹ cr) | Share % |
|---|---|---|
| Core Operations & Products | 165 | 68.5% |
| Retail & Enterprise Services | 62.01 | 21.2% |
| Digital & Technology Solutions | 33.07 | 10.3% |
Core Operations & Products68.5%
Retail & Enterprise Services21.2%
Digital & Technology Solutions10.3%
Source: Company annual report and quarterly segment disclosures. How this data is compiled.
Same Data For Peers
- Metropolis Healthcare Limited business segment revenue
- Medi Assist Healthcare Services Limited business segment revenue
- Morepen Laboratories Limited business segment revenue
- Global Health Limited business segment revenue
- Natco Pharma Limited business segment revenue
- Max Healthcare Institute Limited business segment revenue
Trade Medicamen Biotech With ATS
Track MEDICAMEQ live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.